Suppr超能文献

心脏移植受者对SARS-CoV-2疫苗的免疫反应:一项系统综述

Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review.

作者信息

Shoar Saeed, Prada-Ruiz Adriana C Carolina, Patarroyo-Aponte Gabriel, Chaudhary Ashok, Sadegh Asadi Mohammad

机构信息

Department of Clinical Research, Scientific Collaborative Initiative, Houston, TX, USA.

Division of Pediatric Cardiology, Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, TX, USA.

出版信息

Clin Med Insights Circ Respir Pulm Med. 2022 Jun 5;16:11795484221105327. doi: 10.1177/11795484221105327. eCollection 2022.

Abstract

BACKGROUND

Heart transplant (HTX) recipients are at a significantly higher risk of adverse clinical outcomes, due to chronic immunosuppression and co-existence of other chronic conditions, when contracting the SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently the most promising measure for the prevention of severe Coronavirus Disease 2019 (COVID-19) among solid organ transplant recipients, the extent of immune response and its protective efficacy among patients receiving HTX has not been sufficiently studied.

METHODS

We performed a systematic review of the literature by inquiring PubMed/Medline to identify original studies among HTX recipients, who had received at least one dose of the SARS-CoV-2 vaccine. Data on the measured humoral or cellular immune response was collected from all the eligible studies. Factors associated with a poor immune response were further investigated within these studies.

RESULTS

A total of 12 studies comprising 563 HTX recipients were included. The average age of the study participants was 60.8 years. Sixty four percent of the study population were male. Ninety percent of the patients had received an mRNA vaccine (Pfizer/ BNT162b2 or Moderna/mRNA-1273). A positive immune response to SARS-CoV-2 vaccine was variably reported in 0% to 100% of the patients. Older age (> 65 years), vaccine dose (first, second, or third), time since HTX to the first dose of the vaccine, the time interval between the latest dose of the vaccine and measurement of the immune response, and the type of immunosuppressive regimen were all indicated as potential determinants of a robust immune response to the SARS-CoV-2 vaccination.

CONCLUSION

HTX recipients demonstrate a weaker immune response to the vaccination against SARS-CoV-2 compared to the general population. Older age, anti-metabolite agents such as mycophenolate mofetil, and vaccination during the first year following the HTX have been indicated as potential determinants of a poor immune response.

摘要

背景

心脏移植(HTX)受者感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)时,由于长期免疫抑制以及其他慢性疾病的共存,出现不良临床结局的风险显著更高。尽管目前接种SARS-CoV-2疫苗是预防实体器官移植受者发生重症2019冠状病毒病(COVID-19)最有前景的措施,但在接受HTX的患者中,免疫反应的程度及其保护效果尚未得到充分研究。

方法

我们通过查询PubMed/Medline对文献进行了系统综述,以确定接受至少一剂SARS-CoV-2疫苗的HTX受者中的原始研究。从所有符合条件的研究中收集有关检测到的体液或细胞免疫反应的数据。在这些研究中进一步调查与免疫反应不佳相关的因素。

结果

共纳入12项研究,包括563名HTX受者。研究参与者的平均年龄为60.8岁。64%的研究人群为男性。90%的患者接种了mRNA疫苗(辉瑞/BNT162b2或莫德纳/mRNA-1273)。不同研究报告0%至100%的患者对SARS-CoV-2疫苗有阳性免疫反应。年龄较大(>65岁)、疫苗剂量(第一剂、第二剂或第三剂)、从HTX到第一剂疫苗的时间、最新一剂疫苗与免疫反应测量之间的时间间隔以及免疫抑制方案的类型均被指出是对SARS-CoV-2疫苗产生强劲免疫反应的潜在决定因素。

结论

与普通人群相比,HTX受者对SARS-CoV-2疫苗接种的免疫反应较弱。年龄较大、抗代谢药物(如霉酚酸酯)以及HTX后第一年接种疫苗被指出是免疫反应不佳的潜在决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/9174554/6a742cf15bc6/10.1177_11795484221105327-fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验